Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SMMT 
Summit Therapeutics PLC (SMMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SMMT (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $37.97
Year Target Price $37.97
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 91.53% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.30B USD | Price to earnings Ratio - | 1Y Target Price 35.29 |
Price to earnings Ratio - | 1Y Target Price 35.29 | ||
Volume (30-day avg) - | Beta -1.05 | 52 Weeks Range 6.78 - 36.91 | Updated Date 06/29/2025 |
52 Weeks Range 6.78 - 36.91 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.5% | Return on Equity (TTM) -123.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14944053034 | Price to Sales(TTM) 753.9 |
Enterprise Value 14944053034 | Price to Sales(TTM) 753.9 | ||
Enterprise Value to Revenue 6425.28 | Enterprise Value to EBITDA -5.32 | Shares Outstanding 742665984 | Shares Floating 116056404 |
Shares Outstanding 742665984 | Shares Floating 116056404 | ||
Percent Insiders 84.32 | Percent Institutions 13.52 |
Analyst Ratings
Rating 4.7 | Target Price 37.97 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Summit Therapeutics PLC
Company Overview
History and Background
Summit Therapeutics PLC, formerly known as Summit Corporation PLC, was founded in 2003. It is a biopharmaceutical company focused on developing medicines for unmet medical needs. Initially focused on DMD, it has evolved to target other areas.
Core Business Areas
- Oncology: Summit is currently focused on novel therapies for oncology, particularly in immuno-oncology.
- Duchenne Muscular Dystrophy (DMD): While no longer the core focus, the company has historical ties to DMD research.
Leadership and Structure
Robert W. Duggan serves as Chairman and CEO. The company has a standard organizational structure with executive leadership in finance, research and development, and operations.
Top Products and Market Share
Key Offerings
- ivonescimab: Ivonescimab is their key investigational product, a bispecific antibody targeting PD-1 and VEGF. It is being evaluated in multiple oncology indications. Market share is currently $0 as the drug is still in development. Competitors in the PD-1/VEGF inhibitor space include Roche (Tecentriq), Bristol Myers Squibb (Opdivo) and Merck (Keytruda), which have drugs approved and generating revenue in similar cancer indications
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, characterized by long development timelines and high regulatory hurdles. Oncology is a significant area of investment.
Positioning
Summit is positioned as a research-driven company focused on innovative therapies. Success depends on the clinical trial outcomes and regulatory approvals of ivonescimab.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is estimated to be hundreds of billions of dollars annually. Summit's potential TAM depends on the specific indications for which ivonescimab gains approval. Summit Therapeutics PLC's is positioned in this TAM by bringing a novel Bispecific antibody to compete with Monospecific therapies.
Upturn SWOT Analysis
Strengths
- Novel bispecific antibody platform
- Experienced leadership team
- Strong focus on immuno-oncology
- Positive early clinical data for ivonescimab
Weaknesses
- Reliance on a single lead product candidate (ivonescimab)
- High cash burn rate
- Dependence on successful clinical trials and regulatory approvals
- Limited commercialization experience
Opportunities
- Potential to address unmet needs in various cancer indications
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline through further research and development
- Favorable regulatory environment for innovative therapies
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from established players with approved therapies
- Patent challenges
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Bristol Myers Squibb (BMY)
- Merck (MRK)
Competitive Landscape
Summit faces intense competition from established pharmaceutical companies with significant resources and approved therapies. Their success hinges on demonstrating superior efficacy and safety of ivonescimab.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's developmental stage.
Future Projections: Future growth is dependent on the clinical trial outcomes and regulatory approvals of ivonescimab. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing ivonescimab through clinical trials and expanding into additional cancer indications.
Summary
Summit Therapeutics is a high-risk, high-reward biopharmaceutical company focused on oncology. Its future is heavily reliant on the success of its lead product candidate, ivonescimab. While early clinical data is promising, the company faces significant competition and regulatory hurdles. Positive data and regulatory approvals would represent a huge turning point for this company. Risks for this company include clinical trial failures and competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Company website
- Analyst reports (where available)
- Press releases
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Summit Therapeutics PLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2015-03-05 | Co-CEO & Executive Chairman Mr. Robert W. Duggan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 159 | Website https://www.smmttx.com |
Full time employees 159 | Website https://www.smmttx.com | ||
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.